Search results
Results from the WOW.Com Content Network
A phase I clinical trial is recruiting individuals to study the side effects and efficacy of CD19/CD22 chimeric antigen receptor T cells (i.e. T-cells from a donor patent are obtained, engineered to attack cells that express CD19 or CD22, and then injected back into the donor) when given together with chemotherapy in treating patients with ...
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Blinatumomab linking a T cell to a malignant B cell.. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.
This approach targets both CD19+ B cells and CD70+ T cells, which play a role in autoimmune disease pathogenesis. Additionally, ALLO-329 incorporates Allogene's clinically validated Dagger ® technology, designed to reduce or eliminate the need for lymphodepletion, a pre-treatment regimen that may be a significant barrier to CAR T cell therapy ...
An anti-CD22 immunotoxin is a monoclonal antibody targeting CD22 linked to a cytotoxic agent. As of August 2009, it was studied in the treatment of some types of B-cell cancer. It binds to CD22, a receptor protein on the surface of normal B cells and B-cell tumors , and, upon internalization, kills the cells, acting as immunotoxin .
The tumor cells in Burkitt lymphoma generally strongly express markers of B cell differentiation (CD20, CD22, CD19), as well as CD10 and BCL6. The tumor cells are generally negative for BCL2 and TdT. The high mitotic activity of Burkitt lymphoma is confirmed by nearly 100% of the cells staining positive for Ki67. [23]
The malignant B-cells in THRLBCL are definitively identified by immunophenotyping to detect B-cell marker proteins (e.g. CD19, CD20, CD22, CD79a, and/or PAX5). [4] These cells may also express other identifying marker proteins such as Bcl-6 (50–90% of cases), the product of the MYC gene, c-Myc (most cases), Bcl-2 (40% of cases), MUC1 (30% of ...
CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. [4] It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases .